Home   中文简体 中文繁體 
Company News Products R&D Investor relationship Human Resource Contact Us
Photodynamic technology drugshotodynamic
Nano technology drugs
Genetic engineering drugs
Oral solid preparation technology drugs
Nano technology drugs
Doxorubicin hydrochloride liposome injection (LIBOd®)

        The Company has obtained drug approval issued by CFDA for Doxorubicin Hydrochloride Liposome Injection (LIBOd®), which number is Guo Yao Zhun Zi H20084432 and Guo Yao Zhun Zi H20123224, and officially launch on the market in July, 2009. It is the first PEG modified liposome chemotherapy drug manufactured inside China.
        LIBOd® is doxorubicin hydrochloride (HCl) encapsulated in methoxy polyethylene glycol (MPEG) modified liposomes for intravenous administration. The PEG hydration layer existing on the surface of liposomes can prevent the combination of liposomes and plasma opsonin, thereby protecting liposome from mononuclear macrophage system (MPS) recognition and prolonging the circulation time in blood. LIBOd® exhibits a very different pharmacokinetic property, comparing to conventional doxorubicin hydrochloride injection. The introduction of liposome carrier increases the circulation time of doxorubicin, enhances drug’s accumulation in tumor site through the EPR effect, and reduces the toxic side effects of the conventional drug, such as cardiovascular toxicity, bone marrow inhibition and hair loss.
        LIBOd® is used for the treatment of AIDS-related Kaposi’s sarcoma (AIDS-KS) in patients with low CD4(<200CD4lymph cell/mm3)  and various diseases of skin, mucosa and viscera.
        The product is used as the first-line chemotherapeutic drug or the second-line drug for the AIDS-KS patient whose disease has progressed, also used for the patients who are intolerant to the therapy with following combinations: vincristine, bleomycin and doxorubicin (or other anthracycline antibiotics).
        The product of doxorubicin hydrochloride liposome injection was approved to be used in the treatment of ovarian cancer and bone marrow cancer overseas. 

This page outlines FDZJ drug development portfolio. The content of the portfolio will change over time as new compounds progress from discovery to development. Due to the nature of the drug development process, it is not unusual for some compounds, especially those in early stages of investigation, to be terminated as they progress through development. For competitive reasons, some projects have not been disclosed and some project types may not have been identified.

Links  |  SiteMap  |  Privacy Copyright© Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. 2007
(沪)-非经营性-2019-0143    沪ICP备10027510号-1